Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs General Dynamics Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.7 (market cap $29.60B), while General Dynamics Corporation trades at $392.59 (market cap $106.03B). The key difference: General Dynamics Corporation is far larger — about 3.6× Alnylam Pharmaceuticals, Inc.'s market cap, and General Dynamics Corporation pays a 1.62% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GD | |
|---|---|---|
Market Cap | $29.60B | $106.03B |
Sector | Health | Industrials |
52-Week High | $491.22 | $395.97 |
52-Week Low | $205.48 | $312.53 |
Enterprise Value | $27.56B | $111.17B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
General Dynamics (GD) trades at $395.97, up 1.0% on the day, near its 52-week high. The stock shows bullish technical momentum with consistent earnings beats, including Q2 2026 EPS of $4.24 versus $3.96 expected. Revenue growth is robust, with 2025 revenue at $52.55 billion, and the company secured a major $76.6 billion Navy contract in July 2026, boosting its backlog.
Outlook remains positive driven by defense budget tailwinds and strong contract wins, but valuation multiples like a P/E of 23.9 suggest limited upside from current levels. Risks include execution on large contracts and macroeconomic pressures on government spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
